Combination Therapy of Synthetic DMARDs and Glucocorticoids

The combination of "synthetic DMARDs + glucocorticoid" refers to a treatment approach rather than a single drug. This combination therapy is commonly used in rheumatoid arthritis management, where conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are administered alongside glucocorticoids. ## Key Information Conventional synthetic DMARDs include medications like methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide[3]. Glucocorticoids are anti-inflammatory steroids that can be administered through various routes including oral, intramuscular, intravenous, and intra-articular injections[4]. The combination therapy works by: - csDMARDs targeting the underlying disease process - Glucocorticoids providing rapid symptomatic relief while waiting for the slower-acting DMARDs to take effect[4][5] This approach is often referred to as "bridging therapy," where glucocorticoids bridge the gap between DMARD initiation and their therapeutic effect[5]. The 2019 European League Against Rheumatism guidelines recommend short-term glucocorticoids when initiating or changing conventional synthetic DMARDs[4]. ## Efficacy and Evidence Several studies have demonstrated the effectiveness of this combination: - The CAMERA-II study showed that combining methotrexate with low-dose prednisone for 2 years in early RA patients reduced erosive joint damage progression, disease activity, physical disability, and the need for additional treatments[4]. - The BARFOT trial found that adding 7.5 mg/day prednisolone to csDMARDs for 2 years resulted in better clinical outcomes at all time points up to 24 months compared to csDMARDs alone[5]. - The COBRA study, a landmark trial in early RA, found that treatment regimens with initially higher-dose oral prednisone (60 mg/day, tapering to 7.5 mg/day by week 6 and stopping after week 12) in combination with conventional DMARDs substantially inhibited radiographic joint damage progression[4]. ## Clinical Considerations While effective, this combination therapy requires careful management: 1. Glucocorticoids should be tapered as rapidly as clinically feasible to minimize adverse effects[4][5]. 2. The benefit/risk ratio must be systematically evaluated, even for low-dose glucocorticoids[5]. 3. Glucocorticoids are not recommended as monotherapy and should always be used in combination with DMARDs[5]. 4. Under tight control conditions, methotrexate monotherapy may not be less effective than combination csDMARDs, but is better tolerated[1]. This treatment approach remains an important part of RA management, particularly in early disease or during flares, though the long-term use of glucocorticoids must be balanced against potential toxicity concerns.

Other names

Bridging therapysynthetic DMARDs + glucocorticoid